Trial Profile
Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tobramycin (Primary)
- Indications Pseudomonal infections; Respiratory tract infections
- Focus Therapeutic Use
- Acronyms ELITE
- Sponsors Novartis
- 06 Jan 2010 Planned end date (30 Sep 2007) added as reported by Netherlands Trial Register record.
- 16 Dec 2009 Results were presented in Thorax.
- 13 Dec 2009 New source identified and integrated (ISRCTN: Current Controlled Trials record).